- Current report filing (8-K)
19 3월 2009 - 5:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 17, 2009
VERICHIP CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-33297
|
|
06-1637809
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
1690 SOUTH CONGRESS AVENUE,
SUITE 200
DELRAY BEACH, FLORIDA
|
|
33445
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
561-805-8008
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 1.01. Entry into a
Material Definitive Agreement.
On March 17,
2009, VeriChip Corporation
(“VeriChip”) entered into an exclusive development and supply
agreement with Medical Components, Inc. (“Medcomp”). Pursuant to
the agreement, VeriChip will develop and manufacture a new, smaller RFID
microchip, and Medcomp will purchase the microchip from VeriChip for inclusion
in Medcomp’s vascular access product lines. The initial term of the
agreement is from March 17, 2009 until
five years after the later to occur of (i) the microchip being ready for
production, or (ii) 510k approval of the microchip by the U.S. Food and
Drug Administration. VeriChip will receive a product development fee for the
timely development of the new microchip, and Medcomp will have certain minimum
purchase requirements during the term of the agreement. If all of the minimum
purchase requirements are met, the total value of the contract will exceed
$3 million. Additionally, Medcomp will be responsible for obtaining any
necessary regulatory approvals for use of the product.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release of VeriChip
Corporation dated March 18, 2009
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
VeriChip
Corporation
Date: March 18, 2009
/s/
William J. Caragol
William J. Caragol
Acting Chief Financial Officer
3
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release of VeriChip
Corporation dated March 18, 2009
|
4
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Verichip (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More News Articles